233 related articles for article (PubMed ID: 25046833)
21. Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.
Auner HW; Szydlo R; Hoek J; Goldschmidt H; Stoppa AM; Morgan GJ; Moreau P; Attal M; Marit G; Russell N; Brune M; Cook G; Sonneveld P; Schönland S; Garderet L; Kröger N
Bone Marrow Transplant; 2015 Feb; 50(2):209-15. PubMed ID: 25387088
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma.
Maffini E; Storer BE; Sandmaier BM; Bruno B; Sahebi F; Shizuru JA; Chauncey TR; Hari P; Lange T; Pulsipher MA; McSweeney PA; Holmberg L; Becker PS; Green DJ; Mielcarek M; Maloney DG; Storb R
Haematologica; 2019 Feb; 104(2):380-391. PubMed ID: 30262560
[TBL] [Abstract][Full Text] [Related]
23. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
24. Autologous haematopoietic cell transplantation in elderly patients with multiple myeloma.
Auner HW; Garderet L; Kröger N
Br J Haematol; 2015 Nov; 171(4):453-62. PubMed ID: 26213240
[TBL] [Abstract][Full Text] [Related]
25. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time.
Kumar SK; Dispenzieri A; Fraser R; Mingwei F; Akpek G; Cornell R; Kharfan-Dabaja M; Freytes C; Hashmi S; Hildebrandt G; Holmberg L; Kyle R; Lazarus H; Lee C; Mikhael J; Nishihori T; Tay J; Usmani S; Vesole D; Vij R; Wirk B; Krishnan A; Gasparetto C; Mark T; Nieto Y; Hari P; D'Souza A
Leukemia; 2018 Apr; 32(4):986-995. PubMed ID: 29263438
[TBL] [Abstract][Full Text] [Related]
26. Salvage second hematopoietic cell transplantation in myeloma.
Michaelis LC; Saad A; Zhong X; Le-Rademacher J; Freytes CO; Marks DI; Lazarus HM; Bird JM; Holmberg L; Kamble RT; Kumar S; Lill M; Meehan KR; Saber W; Schriber J; Tay J; Vogl DT; Wirk B; Savani BN; Gale RP; Vesole DH; Schiller GJ; Abidi M; Anderson KC; Nishihori T; Kalaycio ME; Vose JM; Moreb JS; Drobyski W; Munker R; Roy V; Ghobadi A; Holland HK; Nath R; To LB; Maiolino A; Kassim AA; Giralt SA; Landau H; Schouten HC; Maziarz RT; Mikhael J; Kindwall-Keller T; Stiff PJ; Gibson J; Lonial S; Krishnan A; Dispenzieri A; Hari P;
Biol Blood Marrow Transplant; 2013 May; 19(5):760-6. PubMed ID: 23298856
[TBL] [Abstract][Full Text] [Related]
27. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report.
Schriber JR; Hari PN; Ahn KW; Fei M; Costa LJ; Kharfan-Dabaja MA; Angel-Diaz M; Gale RP; Ganguly S; Girnius SK; Hashmi S; Pawarode A; Vesole DH; Wiernik PH; Wirk BM; Marks DI; Nishihori T; Olsson RF; Usmani SZ; Mark TM; Nieto YL; D'Souza A
Cancer; 2017 Aug; 123(16):3141-3149. PubMed ID: 28472539
[TBL] [Abstract][Full Text] [Related]
28. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
[TBL] [Abstract][Full Text] [Related]
29. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma.
Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D
Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040
[TBL] [Abstract][Full Text] [Related]
30. Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation.
Hamadani M; Hari PN; Zhang Y; Carreras J; Akpek G; Aljurf MD; Ayala E; Bachanova V; Chen AI; Chen YB; Costa LJ; Fenske TS; Freytes CO; Ganguly S; Hertzberg MS; Holmberg LA; Inwards DJ; Kamble RT; Kanfer EJ; Lazarus HM; Marks DI; Nishihori T; Olsson R; Reddy NM; Rizzieri DA; Savani BN; Solh M; Vose JM; Wirk B; Maloney DG; Smith SM; Montoto S; Saber W; Alpdogan O; Cashen A; Dandoy C; Finke R; Gale R; Gibson J; Hsu JW; Janakiraman N; Laughlin MJ; Lill M; Cairo MS; Munker R; Rowlings PA; Schouten HC; Shea TC; Stiff PJ; Waller EK
Biol Blood Marrow Transplant; 2014 Nov; 20(11):1729-36. PubMed ID: 25008330
[TBL] [Abstract][Full Text] [Related]
31. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
32. Simplified validated prognostic model for progression-free survival after autologous transplantation for hodgkin lymphoma.
Hahn T; McCarthy PL; Carreras J; Zhang MJ; Lazarus HM; Laport GG; Montoto S; Hari PN
Biol Blood Marrow Transplant; 2013 Dec; 19(12):1740-4. PubMed ID: 24096096
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens.
Maymani H; Lin P; Saliba RM; Popat U; Bashir Q; Shah N; Patel K; Parmar S; Kebriaei P; Hosing C; Ciurea S; Andersson B; Shpall E; Champlin R; Srour SA; Qazilbash MH
Biol Blood Marrow Transplant; 2019 May; 25(5):1039-1044. PubMed ID: 30639822
[TBL] [Abstract][Full Text] [Related]
34. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation.
Cordas Dos Santos DM; Saliba RM; Patel R; Bashir Q; Saini N; Hosing C; Kebriaei P; Khouri IF; Nieto Y; Popat U; Ahmed H; Lee HC; Manasanch EE; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Champlin RE; Qazilbash MH
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1077-1083. PubMed ID: 31786242
[TBL] [Abstract][Full Text] [Related]
35. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.
Scordo M; Wang TP; Ahn KW; Chen Y; Ahmed S; Awan FT; Beitinjaneh A; Chen A; Chow VA; Dholaria B; Epperla N; Farooq U; Ghosh N; Grover N; Hamad N; Hildebrandt GC; Holmberg L; Hong S; Inwards DJ; Jimenez-Jimenez A; Karmali R; Kenkre VP; Khimani F; Klyuchnikov E; Krem MM; Munshi PN; Nieto Y; Prestidge T; Ramakrishnan Geethakumari P; Rezvani AR; Riedell PA; Seo S; Shah NN; Solh M; Yared JA; Kharfan-Dabaja MA; Herrera A; Hamadani M; Sauter CS
JAMA Oncol; 2021 Jul; 7(7):993-1003. PubMed ID: 33956047
[TBL] [Abstract][Full Text] [Related]
36. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect.
Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC
Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma.
Huang J; Phillips S; Byrne M; Chinratanalab W; Engelhardt BG; Goodman SA; Harrell SL; Jagasia M; Kassim A; Rawling KT; Savani BN; Sengsayadeth S; Cornell RF
Bone Marrow Transplant; 2018 Jun; 53(6):701-707. PubMed ID: 29703965
[TBL] [Abstract][Full Text] [Related]
38. Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience.
Chen AI; McMillan A; Negrin RS; Horning SJ; Laport GG
Biol Blood Marrow Transplant; 2008 Jul; 14(7):741-7. PubMed ID: 18541192
[TBL] [Abstract][Full Text] [Related]
39. Autologous/reduced-intensity allogeneic stem cell transplantation vs autologous transplantation in multiple myeloma: long-term results of the EBMT-NMAM2000 study.
Gahrton G; Iacobelli S; Björkstrand B; Hegenbart U; Gruber A; Greinix H; Volin L; Narni F; Carella AM; Beksac M; Bosi A; Milone G; Corradini P; Schönland S; Friberg K; van Biezen A; Goldschmidt H; de Witte T; Morris C; Niederwieser D; Garderet L; Kröger N;
Blood; 2013 Jun; 121(25):5055-63. PubMed ID: 23482933
[TBL] [Abstract][Full Text] [Related]
40. Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.
Oke O; Sethi T; Goodman S; Phillips S; Decker I; Rubinstein S; Concepcion B; Horst S; Jagasia M; Kassim A; Harrell SL; Langone A; Lenihan D; Rawling KT; Slosky D; Cornell RF
Biol Blood Marrow Transplant; 2017 Sep; 23(9):1473-1477. PubMed ID: 28546074
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
